Learning Hub

< BACK State-of-the-art analysis and datasets landscape Nov 6, 2023 Initial review, focusing on the state-of-the-art literature and existing datasets in the field of PsA Psoriatic arthritis is a chronic immune-mediated inflammatory arthritis occurring in patients with PsO. The disease manifestation can be heterogeneous between subjects, and the resulting musculoskeletal impairment can interfere with physical function as well as the quality of life of patients. In a collaborative effort, the iPROLEPSIS partners completed an initial extensive review, focusing on the state-of-the-art literature and existing datasets in the field of PsA, with a special focus on flare dynamics. The primary goal was to enhance the understanding of PsA by investigating disease symptoms, factors associated with flares, and markers for disease development and monitoring. The insights gained from the literature will provide background for various aspects of iPROLEPSIS research, such as investigating PsA inflammation drivers and monitoring, developing the iPROLEPSIS digital health ecosystem for personalised preventive care, and conducting clinical studies. Moreover, various multi-source datasets have been identified that can potentially yield valuable information for the discovery of PsA inflammation drivers and the development of novel digital biomarkers and predictive models for disease monitoring and progression prognosis. The identified datasets will be assessed for relevancy and usability, retrieved, harmonised and curated. These datasets and predictive models will contribute to the research on PsA monitoring and inflammation drivers. In addition, the identified existing datasets will also guide the development of the Lifestyle AI-driven recommendation system and the Serious Games. The key takeaways are: Fatigue, pain and stiffness are commonly reported symptoms in PsA Flare may be triggered by alterations in mood, stress, sleep, bowel movements, and environmental factors Flare may affect mood, stress, sleep, bowel movements, physical activity and fine motor skills Certain symptoms of PsA may also trigger or be triggered by flare Clinical measurements of PsA symptoms and hypothesized flare associated factors, mainly include questionnaires The use of smartphone and wearables to monitor physical activity (mainly through accelerometer data), fine motor skills (through keystroke dynamics), heart rate, heart rate variability have also shown potential to measure PsA symptoms and hypothesized flare associated factors Electrography techniques can also be used in the assessment of certain symptoms and flare associated factors Genetic factors may contribute to development of PsA, pain perception and response to treatment. Gut microbiome may be involved in PsA. MCs in skin are suggested to play a role in skin inflammation Monitoring of PsA can be achieved through clinical examination for inflamed joints, enthesitis dactylitis, nail and skin and subsequent calculation of relative indices and composite scores Imaging-based approaches including images obtained from smartphones and optoacoustics represent a complementary or alternative approach to clinical assessment Data-driven models can serve to find predictive relations even when the underlying mechanisms are poorly understood or are too complex. Recommendations and SGs present a potential approach to modify and improve diet and physical activity Besides diet and physical activity, SGs can also address other aspects of disease, including medication adherence, social support, cognition, breathing, biological and neural function OMOP CDM was opted to be used for standardising the datasets Future steps include an update on state-of-the-art literature and measurement tools on the topics covered by initial research and the identification of new datasets that could be relevant for data-driven models. News & Events iPROLEPSIS - news.png News & Events iPROLEPSIS - news.png 1/1 PREVIOUS NEXT

Learning Hub Explore resources to help you understand and manage psoriatic arthritis. Learning hub Key Facts Handbook News Feed Quizzes Search How will psoriatic arthritis affect me? Relationships and Family Planning See related Handbook section PREVIOUS NEXT

Learning Hub Explore resources to help you understand and manage psoriatic arthritis. Learning hub Key Facts Handbook News Feed Quizzes Search What causes psoriatic arthritis? See related Handbook section PREVIOUS NEXT

< BACK iPROLEPSIS at IEEE-EMBS BSN 2025 Nov 6, 2025 Showcasing iPROLEPSIS at a leading international conference on body sensor research The IEEE-EMBS International Conference on Body Sensor Networks (IEEE-EMBS BSN 2025) took place in Los Angeles, USA, from 3–5 November 2025. The conference brings together researchers, clinicians, and industry representatives working on body sensor technologies and their applications in health and biomedical research. iPROLEPSIS was showcased at the event by project partner PLUX , which hosted a dedicated booth. The project was presented to an international audience, increasing its visibility within the body sensor and digital health research community. IEEE EMBS 2025 2.HEIC IEEE EMBS 2025 1.HEIC IEEE EMBS 2025 3.HEIC IEEE EMBS 2025 2.HEIC 1/3 PREVIOUS NEXT

Learning how to live with psoriatic arthritis might feel like a challenge. But understanding your diagnosis can help you take control of your health. Learning Hub Explore resources to help you understand and manage psoriatic arthritis. Learning hub Key Facts Handbook News Feed Quizzes Search Psoriatic Arthritis Key Facts Key Facts Quizzes about Psoriatic Arthritis Take a Quiz Search about Psoriatic Arthritis Search Psoriatic Arthritis Handbook Handbook News Feed about Psoriatic Arthritis News Feed

The iPROLEPSIS project is where psoriatic arthritis inflammation is explained through multi-source data analysis guiding a novel personalized digital care ecosystem. iPROLEPSIS is a s olution for psoriatic arthritis The iPROLEPSIS project is where psoriatic arthritis inflammation is explained through multi-source data analysis guiding a novel personalised digital care ecosystem. ABOUT CONSORTIUM CONTACT US January 2026 TODAY Mon Tue Wed Thu Fri Sat Sun 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 6 7 8 Upcoming events Psoriatic Arthritis (PsA) is a chronic progressive inflammatory disease affecting 1-2% of the general population, while manifesting in up to 30% of people with psoriasis (PsO). Project vision and impact iPROLEPSIS is a Horizon Europe-funded project developing a novel personalised digital care ecosystem for people with PsA. The goal of iPROLEPSIS is to propose a novel ecosystem that involves Real World Data (RWD) collection mechanisms and a powerful decision support system to provide new knowledge for the key actionable factors that affect the health-to-PsA transition, adopting a multiscale/ multifactorial approach, so, with the use of xAI-based models, to offer an efficient, effective, and clinically validated personalised digital care ecosystem for PsA patients. DISCOVER MORE Project objectives and work packages iPROLEPSIS consortium works on 7 ambitious key objectives in the field of Psoriatic Arthritis (PsA) and has 6 Work Packages of the project that will bring together various and complementary expertise from consortium partners. DISCOVER MORE About project 15 Partners 9 Countries 48 m Project duration € 6,4M Total budget The core activity domains Establishment • The foundation for the project’s research activities is laid by means of an extensive exploration of the available literature and data and the design of the clinical data collection and validation studies; • Participatory design supporting the development of a user-oriented ecosystem of solutions will be employed to establish a framework for trustworthy AI-based R&D. Validation • The design and implementation of the clinical studies that will collect research data, validate the inflammatory symptoms digital biomarkers in individuals at risk of PsA and PSO patients, and evaluate the efficacy of the digital care tools with respect to prevention of inflammation exacerbation. Research and development • Research on multimodal data to reveal key PsA inflammation drivers, provide digital biomarkers of PsA inflammatory symptoms, and explore the effect of PsA on the joints and skin microvasculature, as well as the role of mast cells in PsA transition; • Synthesise the outcomes into a multiscale/multifactorial model of the health-to-PsA transition; • Deliver the integrated iPROLEPSIS digital health ecosystem comprising tools for personalised preventive PsA care, to empower patients and HCPs. Learning Hub Explore resources to help you understand and manage psoriatic arthritis. Handbook Handbook 2 Psoriatic Arthritis Key Facts Key Facts Psoriatic Arthritis Handbook Handbook Quizzes about Psoriatic Arthritis Take a Quiz Project news Handbook Handbook 2 iPROLEPSIS Showcased at MEDICA 2025 Read More iPROLEPSIS at IEEE-EMBS BSN 2025 Read More Seasons Greetings from iPROLEPSIS Read More DISCOVER MORE Contact us We welcome your comments or questions about iPROLEPSIS project! CONTACT US

< BACK iPROLEPSIS Showcased at MEDICA 2025 Nov 25, 2025 Project presented by PLUX at an international medical technology trade fair MEDICA 2025 was held in Düsseldorf, Germany, from 17–20 November 2025 and is one of the largest international trade fairs for medical technology and healthcare. iPROLEPSIS was showcased by project partner PLUX at MEDICA 2025, within a shared exhibition space alongside other Portuguese entities. The event offered an opportunity to present the project to industry and healthcare stakeholders and to engage with a broad international audience. MEDICA 2025 2.HEIC MEDICA 2025 1.HEIC MEDICA 2025 2.HEIC 1/2 PREVIOUS NEXT

iProlepsis psoriatic arthritis project is a comprehensive multiscale model employing novel trustworthy AI-based analysis of multisource and heterogenous data. iPROLEPSIS project objectives and work packages Project aspires to shed light upon the health-to-PsA transition with a comprehensive multiscale / multifactorial PsA model employing novel trustworthy AI-based analysis of multisource and heterogenous (i.a., in-depth health, environmental, genetic, behavioral) data. Project objectives iPROLEPSIS consortium works on 7 ambitious key objectives in the field of Psoriatic Arthritis (PsA). PsA inflamation drivers Discover PsA inflammation drivers through AI-driven health, environmental and omics data mining. Role of mast cells Investigate the role of mast cells and features from non-invasive skin microvascular/joint imaging in inflammatory symptoms tracking. Personalised interventions Develop ICT-based personalised interventions to sustain or even improve quality-of-life. Co-creative ecosystem Co-create the iPROLEPSIS ecosystem with key stakeholders, following ethical, inclusive and trustworthy AI principles. Digital biomarkers Develop and validate objective digital biomarkers for tracking inflammatory symptoms and disease activity. Trustwothy AI models Build trustworthy AI models for personalised PsA risk prediction, early diagnosis and high disease activity prognosis. Digital health ecosystem Develop and clinically validate the iPROLEPSIS digital health ecosystem to empower persons with/at risk of PsA and healthcare professionals. Work packages The 6 Work Packages of the project will bring together various and complementary expertise from consortium partners. WP1 WP2 WP3 WP4 WP5 WP6 Work Package 1: Management and coordination WP1 is dedicated to project management and coordination aiming to enable a smooth project workflow; Ensure optimal contractual, administrative, financial, scientific, technical, IP and innovation management; Assure project quality and safeguard ethics, regulatory compliance and proper data management. Work Package 2: Knowledge mining, foundation and participatory design WP2 aims to create a foundational body of knowledge concerning PsA, associated conditions and inflammation; Identify, retrieve and curate datasets relevant to R&D activities of the project; Identify user needs and effectively engage with key stakeholders for steering research questions and co-creating the iPROLEPSIS digital care tools; Establish and monitor practices for ensuring adherence of iPROLEPSIS AI-driven components to trustworthy AI principles. Work Package 3: Research on PsA inflammation drivers and monitoring WP3 is dedicated to identify drivers related to PsA and associated inflammation leveraging new and existing multi-source health relevant data; Develop smartphone/wearable-based digital biomarkers (dBMs) for assessing PsA inflammatory symptoms; Shed light on changes in the joints and skin microvasculature related to PsA and the role of mast cells in associated inflammation; Through data fusion, develop a multiscale/multifactorial PsA model, emphasising on the prediction of the transition of high-risk individuals and PsO patients to PsA and of PsA patients to advanced inflammatory state. Work Package 4: Development of the iPROLEPSIS digital health ecosystem for personalised preventive care WP4 will technically specify the iPROLEPSIS ecosystem and set up a robust data management infrastructure and DevOps/MLOps platforms; Through an agile approach, develop the iPROLEPSIS minimum viable products (MVPs) for personalised PsA care including: 1) the patient app incorporating (dBM-based)PsA monitoring, knowledge, targeted interventions and tailored AI-driven lifestyle recommendations, 2) the serious gaming suite for health and wellness, 3) the app for HCPs allowing them to remotely monitor patients and view predictions on their course. Work Package 5: Clinical studies WP5 will develop the study protocols and carry out the process for their timely approval by concerned bodies; Set up a system for coordinating recruitment and efficiently managing clinical data and reporting; Organise and conduct four clinical studies: two multicentre prospective cohort studies for discovery and validation of PsA inflammation drivers and digital biomarkers, one observational study on PsA and changes in the joints and skin microvasculature, and one multicentre proof-of-concept randomised controlled trial (RCT) evaluating the effectiveness of the iPROLEPSIS digital care tools. Work Package 6: Dissemination, communication and exploitation WP6 will maximise visibility of the project and its outcomes and facilitate knowledge exchange while engaging a wide network of stakeholders; Develop PsA-related educational content; Set out a roadmap for regulatory approval of the iPROLEPSIS digital tools; Perform a thorough socio-economic/market analysis and develop concrete joint/individual exploitation plans. PROJECT VISION

Learning Hub Explore resources to help you understand and manage psoriatic arthritis. Learning hub Key Facts Handbook News Feed Quizzes Search Quizzes What is psoriatic arthritis? Take a Quiz What are the symptoms of psoriatic arthritis? Take a Quiz How is psoriatic arthritis treated? Drug treatments Take a Quiz How is psoriatic arthritis treated? Self-care and lifestyle Take a Quiz How will psoriatic arthritis affect me? Sleep and Fatigue Take a Quiz How will psoriatic arthritis affect me? Relationships and Family Planning Take a Quiz What causes psoriatic arthritis? Take a Quiz How is psoriatic arthritis diagnosed? Take a Quiz How is psoriatic arthritis treated? Non-pharmacological treatments Take a Quiz How will psoriatic arthritis affect me? Work Take a Quiz How will psoriatic arthritis affect me? Emotional wellbeing Take a Quiz

Data science team Konstantinidis Dimitrios CERTH Position Postdoctoral researcher What is your role in iPROLEPSIS? Researcher and technical developer What are your main activities in the project? I am mainly involved in the research activities of CERTH, concerning psoriatic nail detection and classification, range-of-motion assessment through the execution of active video tests and nutrition and physical activity recommendations. What is your motivation? I am deeply passionate about artificial intelligence and deep learning, with a strong interest in uncovering hidden patterns within data that can lead to highly accurate and reliable predictions. I find great satisfaction in developing advanced machine learning techniques to transform data into innovative solutions that contribute to real-world progress. Nikos Melanitis Ainigma Position Data Scientist What is your role in iPROLEPSIS? Data Scientist, Digital health and predictive modelling What are your main activities in the project? To design and implement novel approaches for improved management of PsA, through personalized models that warn patients for high risk of PsA exacerbation (flare). What is your motivation? To be part of the digital innovation in Health, enabling better disease management and personalised, precision medicine. Kosmas Dimitropoulos CERTH Position Principal Researcher (Researcher of Grade B’) What is your role in iPROLEPSIS? Principal Investigator for CERTH What are your main activities in the project? I am mainly involved in the research activities of CERTH, concerning psoriatic nail detection and classification, range-of-motion assessment through the execution of active video tests and nutrition and physical activity recommendations. What is your motivation? I am deeply motivated by the intersection of Artificial Intelligence and healthcare. I aspire to contribute to research that applies deep learning techniques to personalized medicine, enabling more accurate, data-driven, and patient-specific approaches to diagnosis and treatment. Eleni Vasileiou Signal Processing & Biomedical Technology Unit (SPBTU) – Aristotle University of Thessaloniki (AUTH) Position Research assistant working on digital health technologies and AI-enabled healthcare tools What is your role in iPROLEPSIS? AI Researcher & Data Scientist | Digital health and predictive modelling What are your main activities in the project? My main activities focus on developing digital, passively captured indicators that support risk prediction and monitoring models for psoriatic arthritis. I work on digital phenotyping of inflammatory symptoms with an emphasis on tracking motor manifestations using smart devices and wearables. This involves designing methods to analyze data from daily living activities – such as sleep, walking, and hand movements – to capture subtle physiological and behavioral changes associated with disease onset and progression. These efforts aim to identify key drivers of psoriatic arthritis and support personalized models for disease risk, progression prediction, and inflammation monitoring. What is your motivation? I am deeply motivated by the potential of digital health technologies to bring a more human and data-informed approach to healthcare. By combining AI with continuous, real-world data, we can reveal patterns often hidden in traditional clinical assessments. What drives me is the belief that these insights can empower both patients and clinicians to make earlier and more informed decisions, ultimately improving health outcomes and quality of life. My goal is to contribute to a future where technology enhances understanding, prevention, and personalized care for chronic conditions. Coordination Clinical Experts Data Science Software Development Ethics, Legal and Exploitation Dissemination and Communication

Learning Hub Explore resources to help you understand and manage psoriatic arthritis. Handbook Learning hub Key Facts Handbook News Feed Quizzes Search Handbook 1 Psoriatic Arthritis Handbook Understanding Psoriatic Arthritis h1.1 What is psoriatic arthritis? Psoriatic arthritis is a type of arthritis linked with psoriasis, a chronic skin and nail disease. Psoriasis causes red, scaly rashes and thick, pitted fingernails. Psoriatic arthritis is characterized by joint swelling (inflammation), pain and stiffness and can affect any peripheral joint such as fingers, toes, knees and/or spine. It also affects the insertion of tendons or ligaments in bones (enthesitis). Between 20-40% of people with the skin condition psoriasis will develop psoriatic arthritis (1, 2). Symptoms affecting their joints tend to develop 5 to 10 years after psoriasis is diagnosed but it can occur at any time (3). Currently, it is not clear why some people with psoriasis develop psoriatic arthritis while others do not. The arthritis of psoriatic arthritis comes in 3 forms: oligoarticular arthritis that affects 4 or less peripheral joints (e.g., joints in the fingers, toes, knees); polyarticular arthritis that involves 5 or more peripheral joints on both sides of the body; and axial arthritis that affects the joints of the spine including the sacroiliac joint (where the spine connects to the pelvis). Some people may develop psoriasis after or at the same time as symptoms of psoriatic arthritis present themselves (4). In rare cases, people may have psoriatic arthritis and never have any noticeable symptoms of psoriasis. Psoriatic arthritis and psoriasis are chronic inflammatory conditions that are caused by a fault in the immune system. Our immune system protects us from infection and illness. See related Key Facts section What causes psoriatic arthritis? While psoriatic arthritis can occur at any age, most people present their first signs and symptoms at 30-50 years. Psoriatic arthritis is most likely to be diagnosed within the first ten years of the psoriasis diagnosis (3). Psoriatic arthritis affects both sexes equally. However, the manifestations in terms of severity and impact of the disease differ between sexes. Men are more likely to have involvement of the bones in the spine (axial arthritis) and radiographic damage in the spine and peripheral joints (e.g., fingers, knees and toes), whereas women are more likely to experience impaired quality of life and severe limitations in function (5). Researchers are not sure why some people develop psoriatic arthritis. It is thought that certain genes inherited from parents and grandparents can make a person more likely to develop psoriatic arthritis (6–8). h1.2 In people with a higher genetic predisposition to develop psoriatic arthritis, the condition can be triggered by environmental factors, such as: an infection (9); an accident or injury (10, 11); being overweight (12); smoking (13, 14). Psoriasis and psoriatic arthritis are not contagious. You cannot catch psoriasis or psoriatic arthritis from other people. See related Key Facts section What are the symptoms of psoriatic arthritis? Psoriatic arthritis symptoms usually develop slowly, that is, many people are unaware that they are developing psoriatic arthritis (Figure 1). Although symptoms can develop suddenly in rarer cases. Some of the main symptoms include (15): pain in one or more joints; swelling in one or more joints; stiffness in one or more joints that lasts for 30 minutes or longer. These symptoms are caused by inflammation and can affect any joint in the body. See Figure 2 for the most commonly affected joints. See related Key Facts section h1.3 Psoriatic arthritis can cause pain and swelling in the entheses, that is, places in the body where tendons and ligaments connect to the bones (15). When the entheses become inflamed it is known as enthesitis. Enthesitis pain can spread along a wider area than joint pain. It frequently occurs at the back of the heel or on the bottom of the foot, which can make standing or walking difficult. Affected areas feel tender to touch even when just a small amount of pressure is applied. The knees, hips, elbows and chest can also be affected by enthesitis. Many people with psoriatic arthritis have swollen fingers or toes, a condition that is known as dactylitis (15) (Figure 1). It most commonly affects one or two fingers or toes at a time. Psoriatic arthritis can also cause small round dents in fingernails and/or toenails, a condition known as pitting. The nails can change colour, become thicker, or even lift away from your finger (15). People living with psoriatic arthritis may feel very tired (fatigued) and some may have a low-grade fever. Fatigue does not get better with rest. Psoriatic arthritis symptoms may come and go. A period of increased inflammation and worsening of other symptoms is called a flare. A flare can last for days or months See related Key Facts section h1.5 How is psoriatic arthritis diagnosed? A timely and accurate diagnosis is an important step for optimising care and improve long-term health outcomes (16). If you have been diagnosed with psoriasis in the past, and symptoms of arthritis (e.g., painful or swollen joints) have started more recently, you may have developed psoriatic arthritis. However, the symptoms of psoriatic arthritis can look like other health conditions. Make sure to see your healthcare provider for a diagnosis. The doctor you see first may depend on whether you have previously been diagnosed with psoriasis. If you develop symptoms of arthritis your primary care or skin doctor should refer you to a rheumatologist – a doctor who specialises in joint conditions – for an assessment. Tell your doctor if you have a history of psoriasis and/or psoriatic arthritis in your family. CURRENTLY, NO SINGLE TEST CAN CONFIRM PSORIATIC ARTHRITIS (15). A diagnosis will be made based on your medical history, symptoms, and a physical examination by your doctor. Your doctor may order X-rays or other types of imaging, such as ultrasound scans and magnetic resonance imaging (MRI), to look for changes to your bones and joints. Imaging studies will help your doctor determine the type and pattern of joint involvement, which can also help them distinguish between arthritis types. Blood tests, such as erythrocyte sedimentation rate and C-reactive protein, can help to identify inflammation. Your doctor may also order tests for rheumatoid factor and the anti-CCP antibody to rule out rheumatoid arthritis and HLA-B types to look for your genetic predisposition to spondylarthritis. See related Key Facts section h1.4 See related Key Facts Previous page Next page

Welcome to our collaborative initiative, a dedicated networking subpage showcasing the synergistic efforts of innovative projects. iPROLEPSIS networking activities Our shared vision is to establish a robust ecosystem of initiatives , where the combined strength of each project contributes to the overarching goal of advancing healthcare and well-being. By pooling our resources, knowledge, and expertise, we believe in the potential for significant benefits both for the collaborative cluster and the individual projects involved. Networking projects funded under the call HORIZON-HLTH-2022-STAYHLTH-02-01 CARE-IN-HEALTH Cardiovascular REsolution of INflammation to promote HEALTH WEBSITE Cardiovascular diseases (CVD) are the leading cause of mortality in Europe (1.9 million of annual deaths). CVD are significant public health challenge, accounting for €200 billion in economic burden annually in Europe. Lipid-mediated chronic inflammation and particularly the failure in the resolution of the inflammation, is a particular critical risk factor for the transition from health to CVD. CARE-IN-HEALTH addresses this by aiming to identify the pathways involved in the resolution of the lipid-mediated inflammation to prevent and reverse inflammation and therefore CVD. The interdisciplinary consortium will collect and integrate epidemiological, multi-omics, and immune data to create the CARE-IN-HEALTH Atlas, which will be openly accessible to the scientific community. Such a knowledge base will allow to systematically identify and validate individual’s critical immune pathways. A CARE-IN-HEALTH MCDSS (multi-criteria decision support system) will guide healthcare professionals to design personalised CVD prevention strategies. The CARE-IN-HEALTH BIOSENSOR will monitor inflammation resolution for citizens. CARE-IN-HEALTH will demonstrate proof-of-concept for an appropriate lipid intake as dietary intervention and specifically, for the use of vegetal omega-3 fatty acid sources as substrates for immunomodulatory lipid mediators and resolution of inflammation. All this is based on the results of a proof-of-concept clinical trial. GlycanTrigger Glycans as master triggers of health to intestinal inflammation transition WEBSITE GLYCANTRIGGER - Glycans as master triggers of health to intestinal inflammation transition. The GlycanTrigger project proposes a thorough and innovative approach to understand better the health-to-chronic inflammation transition occurring in patients with Crohn’s Disease that will be translated into improved disease prediction and prevention. The project will address how changes in glycosylation of the gut mucosa act as a primary event that dysregulates not only local mechanisms but also systemic mechanisms, involving the novel concept of glycan mimicry as an early trigger of the health-to-inflammation transition. The long-term goal of this project is to unlock a new checkpoint that regulates the transition to chronic inflammation, aiming to figure out how to turn off this process by developing novel preventive intervention strategies. halt-RONIN Discovering chronic inflammation biomarkers that define key stages in the Healthy-to-NASH (non-alcoholic steatohepatitis) transition to inform early prevention and treatment strategies. Downolad PDF to read more. WEBSITE NAFL (non-alcoholic fatty liver) is the most widespread subtype of NAFLD, a highly prevalent inflammation-related disease, characterized by steatosis, relatively benign and reversible condition, which can progress to the more serious progressive stage of non-alcoholic steatohepatitis (NASH), in which steatosis is accompained by lipotoxicity, mitochondrial dysfunction and a high state of inflammation and fibrosis. IMMEDIATE Imminent Disease Prediction and Prevention at the Environment Host Interface WEBSITE The EU-funded research project IMMEDIATE strives to identify individual biomarkers of risk and resilience against chronic inflammation by investigating the diet-microbiome-metabolite-immune axis. This complex interaction refers to how an individual's diet, gut microbiota, metabolites, and immune system can influence their health. IMMEDIATE will use cutting-edge technologies and clinical and metadata from large observational cohort studies to identify pre-disease stages and further our understanding of the mechanisms and molecular pathways underpinning non-communicable diseases. Furthermore, a proof-of-concept study on healthcare professionals will be conducted to test the effectiveness of a probiotic intervention and ultimately develop mobile apps designed to offer personalized lifestyle recommendations and empower citizens to manage their own health proactively. INITIALISE Inflammation in human early life: targeting impacts on life-course health WEBSITE INITIALISE (Inflammation in human early life: targeting impacts on life-course health) is an EU funded project that aims to elucidate how exposures and genome impact gut microbiome, host immune system and metabolism, and how the interplay of these factors impact life-course health.  INITIALISE aims to define the role of the maturation of the immune system as a mediator between exposures and life-course health. INTERCEPT-T2D Early Interception of Inflammatory-mediated Type 2 Diabetes WEBSITE Inflammatory-based interceptive medicine in type 2 diabetes Individuals with type 2 diabetes (T2D) do not use insulin efficiently and, therefore, their glucose levels rise. T2D is a heterogeneous disease, which is an obstacle to the delivery of an optimal tailored treatment. Consequently, patients’ individual trajectories of progressive hyperglycaemia and risk of chronic complications such as stroke, heart attacks, nephropathy and retinopathy are so far difficult to predict. Chronic systemic inflammation has been suggested to be a major contributor to the onset and progression of T2D complications. The EU-funded INTERCEPT-T2D project will bring a new and clinically relevant dimension in T2D care considering at diagnosis inflammatory parameters that are of importance for the transition to T2D-related complications. Moreover, the project will help deliver optimal treatments tailored to patient needs and conduct a clinical trial to evaluate the efficacy of anti-inflammatory strategies. miGut-Health Personalised blueprint intestinal health WEBSITE The miGut-Health project is an EU-funded initiative that is developing novel strategies to predict and prevent inflammatory bowel disease (IBD). miGut-Health aims to create personalised patient engagement strategies for predicting and monitoring preclinical IBD by focusing on the transitory phase from health to disease. The overarching goal is to provide strategies for early disease prediction, prevention and gut health improvement for people affected by IBD, high-risk individuals and citizens. AIDA An Artificially Intelligent Diagnostic Assistant for gastric inflammation WEBSITE Most cases of gastric cancer (GC) are detected at a late stage, when patients have a median life expectancy of about a year. Diagnosing people at risk of developing GC at the pre-symptomatic stage, typically chronic gastric inflammation, could significantly improve the outlook. Artificial intelligence (AI) can help clinicians make sense of their own data by automating much of the treatment and analysis, which require manual work and years of experience. But it can do more: it can bring together available data from various sources into a vast data lake and cross-correlate the data to derive a ‘risk score’ for gastric cancer and shed light on the mechanisms of its evolution. Aida aims to do just that. It helps researchers understand the mechanisms that trigger gastric oncogenesis, helps clinicians diagnose precancerous inflammation at the earliest possible stage, suggests personalised therapeutic strategies for treatment and follow-up, and makes personalised recommendations for monitoring patient health status, thus contributing to gastric cancer prevention. This places Aida squarely on Europe’s agenda of ‘Staying healthy in a rapidly changing society’. Aida unites some of Europe’s leading authorities in the field of gastric inflammation, gastric cancer, leading AI and machine learning experts, experts on data governance and privacy, representatives of the public administration and patient advocates. Aida also has strong ties with the industry. After the project, the results will live on in a foundation that acts as a transnational focal point for chronic gastric inflammation — and GC in general. We hope that the solid, inclusive design principles of Aida, its societal relevance and its durability will spawn a vigorous ecosystem around chronic gastric inflammation, its understanding and its treatment. And we hope that it will inspire other data collaboratives in health — for other chronic inflammations, other forms of cancer or other ailments altogether. PROTO Advanced Personalized Therapies for Osteoarthritis WEBSITE Osteoarthritis (OA) is a chronic progressive joint disorder, characterized by inflammation causing pain, stiffness, swelling and gradual loss of joint function. PROTO aims to halt and partially reverse the structural and functional changes caused by inflammatory processes in OA Our ambitious goal is to introduce: a highly innovative anti-inflammatory local placental derived cell therapy in early-stage OA patients and a personalized sensor-based training intervention intended to prevent inflammation and OA onset during a crucially important ‘window of opportunity’ by correcting pathological movement patterns in pre-stage OA patients. ENDOTARGET Sytemic Endotoxemia as the driver of chronic inflammation–Biomarkers and novel therapeutic targets for Arthritis WEBSITE ENDOTARGET explores the relationship between gut microbiota, gut permeability, and systemic endotoxemia with a special focus on the three most abundant rheumatic diseases (RDs): osteoarthritis, rheumatoid arthritis and spondylarthritis. The aim is to clarify (1) the role of the three factors gut microbiota, gut permeability and systemic endotoxemia in RD onset and pathogenesis, (2) which events and mechanisms are responsible for the origin of RDs, and (3) the influence of the gut microbiota on the joints. Based on the gained knowledge, e.g. new biomarkers for risk assessment will be identified and a Rheumatic disease risk prediction tool (RDPT) will be developed to support clinicians in the classification of patients and to treat RDs preventively. This tool will help to reduce the risk of RD onset and/or to reduce disease activity. PRAESIIDIUM Real-time prediction of the prediabetes risk WEBSITE PRAESIIDIUM will develop a tool based on artificial intelligence coupled with multi-scale, multi-organ integrated mathematical equations for the real-time prediction of the prediabetes risk of an individual. The prediction algorithm will draw on a rich set of information for training, derived from prior clinical data, the individual’s family history, and a pilot study testing wearable sensors that will provide glucose, bioimpedance, and heart rate monitoring. The PRAESIIDIUM platform will be made available to healthcare professionals and patients for an easier data entering and results query and it will be linked to common wearable sensors to monitor the physical activity. PREVALUNG EU Biomarkers affecting the transition from cardiovascular disease to lung cancer: towards stratified interception WEBSITE The project PREVALUNG EU will harness retrospective and prospective cohorts of both CVD patients and LCDT eligibles to develop actionable biomarkers and validate the four classifiers detecting high-risk individuals before or pre-symptomatic of LC, exploiting the latest advances of system biology omics (metabolomics, metagenomics, immunomics, proteomics, and aging-associated BM stem cell genomics) that correlate with uncontrolled inflammatory status of CVD patients. In particular, using four types of diagnosis tools harnessing either of the four drivers of overt inflammation (metabolism, gut dysbiosis, stem cell mutational status, innate immunity), we shall stratify the CVD patient population and leverage the PLCOm2012 risk score to better identify LC high-risk individuals. We will propose a personalized interceptive measure, whose efficacy will be monitored using PREVALUNG EU Focus Panels. We will robustly validate clinical applications, workflows, and tools for easy and broad adoption of the interceptive system across European public care centers and private stakeholders.